1. Home
  2. STSS vs GRML Comparison

STSS vs GRML Comparison

Compare STSS & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sharps Technology Inc.

STSS

Sharps Technology Inc.

HOLD

Current Price

$1.84

Market Cap

43.8M

Sector

Health Care

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.39

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STSS
GRML
Founded
2017
N/A
Country
United States
United States
Employees
55
5
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
51.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
STSS
GRML
Price
$1.84
$0.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
246.3K
3.0M
Earning Date
04-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.27
52 Week High
$18.23
$0.55

Technical Indicators

Market Signals
Indicator
STSS
GRML
Relative Strength Index (RSI) 47.21 46.43
Support Level $1.66 $0.31
Resistance Level $2.00 $0.43
Average True Range (ATR) 0.10 0.05
MACD -0.02 -0.01
Stochastic Oscillator 18.75 27.24

Price Performance

Historical Comparison
STSS
GRML

About STSS Sharps Technology Inc.

Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: